AstraZeneca's (AZN) Q4 Earnings and Sales Miss Estimates changed
Zacks.com (Published: 14-Feb 2020 9:21, Received: 10:00:54)
Word Count: 1231
AstraZeneca PLC price-consensus-eps-surprise-chart | AstraZeneca PLC Quote
Zacks Rank & Stocks to Consider
AstraZeneca currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks worth considering in the pharma/biotech sector include Novartis AG NVS and Vertex Pharmaceuticals Incorporated VRTX, both carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (strong Buy) stocks here.
Novartis’ earnings estimates have moved 0.4% north for 2020 over the past 60 days. The stock has rallied 10.6% in the past year.
Vertex’s earnings estimates have been revised 13.5% upward for 2020 over the past 60 days. The stock has jumped 33.7% in the past year.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AstraZeneca PLC (AZN): Free Stock Analysis Report
Merck & Co., Inc. (MRK): Free Stock Analysis Report
Novartis AG (NVS): Free Stock Analysis Report
Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report